PlainMeds research, FDA and CMS files of October 8, 2026
Brands whose listed protections end by 2028, with no generic approved
29 medicines with no approved generic application have their last Orange Book patent or exclusivity ending between 2026 and 2028.
What the data shows
| Medicine | Reference brand | Last listed patent | Exclusivity ends |
|---|---|---|---|
| Teduglutide | Gattex Kit | 2026-05-01 | |
| Histrelin | Supprelin La | 2026-06-16 | |
| Sinecatechins | Veregen | 2026-10-02 | |
| Treosulfan | Grafapex | 2026-10-12 | |
| Telavancin | Vibativ | 2027-01-01 | |
| Olodaterol | Striverdi Respimat | 2027-01-19 | |
| Chlorpheniramine and ibuprofen and pseudoephedrine | Advil Allergy Sinus | 2027-02-28 | |
| Bazedoxifene and estrogens conjugated | Duavee | 2027-03-10 | |
| Chlorhexidine and isopropyl alcohol | Chloraprep One-Step | 2027-04-25 | |
| Florbetapir f 18 | Amyvid | 2027-04-30 | |
| Avatrombopag | Doptelet | 2027-07-28 | |
| Uridine triacetate | Xuriden | 2027-08-17 | |
| Belinostat | Beleodaq | 2027-10-27 | |
| Umeclidinium | Incruse Ellipta | 2027-12-18 | |
| Istradefylline | Nourianz | 2028-01-28 | |
| Dienogest and estradiol | Natazia | 2028-01-30 | |
| Ciclesonide | Omnaris | 2028-02-01 | |
| Isavuconazonium | Cresemba | 2028-03-14 | |
| Vorinostat | Zolinza | 2028-03-18 | |
| Edoxaban | Savaysa | 2028-03-28 | |
| Macimorelin | Macrilen | 2028-04-12 | |
| Flibanserin | Addyi | 2028-05-09 | |
| Pasireotide | Signifor Lar Kit | 2028-05-23 | |
| Quazepam | Doral | 2028-06-03 | |
| Golodirsen | Vyondys 53 | 2028-06-28 | |
| Trabectedin | Yondelis | 2028-07-07 | |
| Vandetanib | Caprelsa | 2028-08-08 | |
| Flutemetamol f 18 | Vizamyl | 2028-09-16 | |
| Vismodegib | Erivedge | 2028-12-15 |
Source: FDA Orange Book and Drugs@FDA, read October 8, 2026
How it was measured
Orange Book patents and exclusivities (openFDA bulk), the last expiry per medicine, for medicines Drugs@FDA lists with no approved ANDA.
What it cannot show
A listed expiry is not a launch date: new patents, pediatric exclusivity, litigation and settlements move generic entry either way, and unlisted patents exist.